Purpose We estimated the proportion of patients who received neoadjuvant chemotherapy
for muscle-invasive bladder cancer whose tumors were downstaged by transurethral …

Objective To evaluate variation in neoadjuvant chemotherapy (NAC) use among patients
with≥ clinical T2 (cT2) bladder cancer and determine changes in staging at radical …

Introduction There is controversy regarding the benefit of a grossly complete transurethral
resection of bladder tumor (TURBT) for muscle-invasive bladder cancer (MIBC) in patients …

Objectives Prior studies have shown that pathologic complete response at radical
cystectomy, a significant prognostic factor, can be attributed to both neoadjuvant …

Purpose Previous studies have noted increased utilization of perioperative chemotherapy
over time. The goal of this study was to determine trends in perioperative chemotherapy use …

Background The use of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) is
supported by results from several randomized control trials, including SWOG-8710 …

Materials and methods A retrospective review of all patients who underwent radical
cystectomy (RC) between 2008 and 2012 was performed. Information on clinical and …

Context Neoadjuvant chemotherapy (NAC) is recommended prior to radical cystectomy in
the setting of muscle-invasive bladder cancer. Despite a 5–10% survival benefit, some …

Background The efficacy of neoadjuvant chemotherapy (NAC) for muscle-invasive bladder
cancer (BCa) was established primarily with methotrexate, vinblastine, doxorubicin, and …

Background Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle invasive bladder
cancer improves all-cause and cancer specific survival. We aimed to evaluate whether the …